(i) severity of arthritis ↓(ii) TNFα, IL-6, and CRP levels ↓(iii) elimination of adalimumab ↓(iv) did not inhibit the production of anti-adalimumab antibodies(v) FcRn levels ↑. This evidence concerns the gene TNF and arthritic joint disease.